![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA RELEASES GUIDANCE ON OUT-OF-SPECIFICATION TEST RESULTS
FDA RELEASES GUIDANCE ON OUT-OF-SPECIFICATION TEST RESULTS
In an effort to help pharma manufacturers evaluate test results, the FDA is issuing a new guidance on investigating out-of-specification (OOS) results that fall outside the acceptance criteria established in drug applications, drug master files, official compendia or by the manufacturer. The designation also covers in-process laboratory tests.
The document, "Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production," was published in the Oct. 12 Federal Register. It discusses such topics as:
- How to investigate OOS test results;
- The laboratory phase of the investigations;
- Responsibilities of laboratory personnel, such as the analyst and supervisor;
- When to expand the investigation outside the laboratory to include the production process and raw materials;
- Additional testing that may be necessary; and
- The final evaluation of all test results.
In response to comments on a 1998 draft version of the guidance, the FDA has revised the scope and background sections of the document to clarify its applicability; reorganized the sections on investigating OOS results, averaging and concluding the investigation; and clarified or added specifics on certain issues.
The guidance can be seen at www.fda.gov/OHRMS/DOCKETS/98fr/98d-0777-gdl0002.pdf.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct